17 January 2017
News and Views
Links and Services
A study in the latest Alimentary Pharmacology & Therapeutics reviews integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
5-Aminosalicylates (5-ASA) are first-line treatment for mild–moderately active ulcerative colitis
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors